{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "", "close" : "", "flags" : {"h" : "Thanksgiving Day"}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
prnewswire

Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award

  • Press Release
  • Source: Cambrex Corporation
  • On 6:16 pm EDT, Wednesday September 16, 2009

EAST RUTHERFORD, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM - News) announced today that its Continuous-Flow Microwave-Assisted Organic Synthesis (CF-MAOS) technology has been accepted as a nominee for the 2009 Innovations Awards at CPhI, an important upcoming pharmaceutical ingredients exhibition to be held in Madrid, Spain.

Related Quotes

SymbolPriceChange
CBM5.64-0.17
Chart for CAMBREX CP
{"s" : "cbm","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The CF-MAOS technology represents a dual technological breakthrough, allowing both the scale-up of microwave-assisted chemistry and the handling of heterogeneous mixtures in continuous-flow. This new technology will finally bring the benefits of both technologies out of the laboratory and into production. The CaMWave(TM) KiloLAB flow reactor is capable of manufacturing in excess of 20 kilograms of product per day, and combined with larger reactors, can generate more than one hundred metric tons of product per year. This versatile technology facilitates faster, cleaner, more reliable reactions, leading to improved productivity and lower manufacturing costs.


    The technology will be presented during the CPhI Innovation Awards:

    Title:        Microwave Chemistry - Out of the Lab and Into Production
    Speaker:      Dr. Jayne E. Muir
    Date:         October 13, 2009
    Location:     Hall 10, Stand 10G16
    Time:         11:00-11:20 a.m.

    Visit Cambrex at CPhI in Madrid at Feria de Madrid Hall 3, Stand 3C70 on
    October 13-15, 2009.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients ("API"), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. For more information, please visit www.cambrex.com.

Sponsored Links

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.